AGM Summar29 Sep 2020 17:10
Much props for Tay for summarising AGM. He'll get a tweet out tomorrow.
Excellent meeting, some massive figures within the detail.
Q. Are manufacturing sub contractors eroding profit?
A. No - they went from reserach use products to clinical
. Margin have been maintained as Clinicial products offer higher profit margins, offsetting the need to outsource manufacturing
. UK Corporration tax is 19% but they're reducing it through the UK's 'Patent Box' scheme. Takes their tax down to 10 to 12%
. Recruited 60+ staff members
. 20 mill cash in bank June AFTER increasing inventory by 13 million and clearing over 8 million in debts
. wanted to take opportunity as early as possible to become debt free
. Now - investing in inventory. Their selling point now is that they can make significant amounts of stock but ALSO deliver fast when needed
. NCYT does not have high capital expenditure, expanded by being efficient and using outsourcing
. manufacturing increased 100 times in 4 months since Feb
. US is largest COVID market and one of Novacyt’s top preforming countries. Nova are developing relationships to increase market share (see question 6)
. Commitment to CONTINUE to innovate as pandemic continues
. Saliva trial currently in London and care Homes
. Major care homes trails are coming to an end
. Transformational contract! (see RNS)
. Phase 1 - £250 million contract can go up. or down.. depends how well NHS use reagents
. Phase 2 - contarct determined by. success of Phase 1.
. I estimate Phase 1 & 2 contracts could be worth £500m > £750m over 12 months
. UK is currently their only direct prescence in a key market.. but they will change that now
. they will add revenues and growth to offset loss of covid 19 in the fture
. COVID-19 revenue will NOT drop off in the near future. In fact they believe COVID testing will increase
. They have competitive advantage as they work close with government and DSC
. Expect to SIGNIFICANTLY exceed 2020 1st half sales
. Continued and very strong sales into 2021 and they cant see a drop off point at this stage
. Market will be updated
. They see no material change in margins any time soon (83% to 85%)
ACQUISITIONS:
. They going to move rapidly, Q1 and Q2 2021, Big acquisitions
Q&A:
1 - Current and future plans and supply constraints?
1A - they built a. flexible supply chain and manufacturing
2 - Plans for products in covid 19 after antobody test release?
2A. - Commited to innovate in covid 19 testing AND in respiratory markets, they WILL address unmet needs. Will update at later date
3 - France progress with 2 gene?
3A - Test now available and reimburseable
4 - Beyond COVID-19 what are next areas?
4A - Market areas in respiratory and clincal diaagnostic markets
5 - How do you see competeition, NCYTs USP, risks, oipportunities as CEO?
5A - total market 70 billion and EXCLUDES. covid 19 testing, some analysts repor